ACR Convergence 2025

October 24-29, 2025. Chicago, Illinois.

View by Number View by Title View Sessions

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

Abstract Number: 1296

Liver Biopsy Findings in Pediatric SLE: A Large Tertiary Center Experience
Abstract Number: PP08

Living Well Despite the Challenges of Sjögren’s Disease and Systemic Lupus Erythematous: My Perspective as a Health Care Provider and Patient
Abstract Number: 0976

LMPTP Drives Fibrosis in Systemic Sclerosis via TGF-beta Signaling Activation
Abstract Number: 1537

Local Immune effector Cell-Associated Toxicity Syndrome (LICATS) in CAR T-cell treated patients with Autoimmune Disease
Abstract Number: 2276

Long-Term Cardiovascular Risk Following Tnfi vs Triple Therapy: A Post-hoc Analysis Integrating Randomized Clinical Trial and Electronic Health Record Data
Abstract Number: 2656

Long-term effect of selexipag in systemic sclerosis-associated digital ulcers: a case control, multicentre, observational study
Abstract Number: 1520

Long-Term Effects of Obinutuzumab on Kidney Function in Lupus Nephritis
Abstract Number: 2362

Long-Term Efficacy and Safety of Risankizumab for csDMARD-IR Patients With Active Psoriatic Arthritis: 244-Week Results From the KEEPsAKE 1 Trial
Abstract Number: 0582

Long-Term Efficacy and Safety of Tofacitinib in Active Axial Spondyloarthritis: Experience from a Tertiary Care Center in South India
Abstract Number: 0420

Long-term efficacy of intra-articular triamcinolone hexacetonide injections in juvenile idiopathic arthritis patients starting tumor necrosis factor inhibitor therapy: 48 weeks results from a randomized, open-label, blinded-assessor multicenter phase 4 trial – the MyJIA trial
Abstract Number: 1447

Long-term impact of secukinumab on the prevention of psoriatic arthritis in patients with psoriasis: a 5-year pooled analysis of the ERASURE, FIXTURE and SCULPTURE studies
Abstract Number: 1493

Long-Term Outcomes in Systemic Lupus Erythematosus Patients Infected with SARS-CoV-2: Variant-Specific Analysis of Pre-Delta/Delta and Omicron Periods
Abstract Number: 2279

Long-Term Prevention of RA in high-risk individuals after a 6-Month Placebo-Controlled Intervention with Abatacept -The ARIAA Trial
Abstract Number: 1432

Long-term Radiographic Progression in Early versus Established Axial Spondyloarthritis: A 12-Year Observational Study
Abstract Number: 1443

Long-Term Safety and Efficacy of Upadacitinib in Patients With Psoriatic Arthritis: 5-Year Results From the Phase 3 SELECT-PsA 1 Study

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].